# US 2020/0368161 A1 · Tumor pH-shiftable coating and the nucleus-directed nanoparticles facilitate the targeted chemotherapy and gene therapy against multiple cancers and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368161 A1
- Document ID: US20200368161A1
- Status: Published application
- Kind: A1
- Application number: 16/858,261
- Filed: 2020-04-24
- Published: 2020-11-26
- Earliest claimed: 2019-04-26
- Assignees: National Yang-Ming University
- Applicants: National Yang-Ming University
- Inventors: Yu-Li LO
- Web page: https://patentgrep.com/patent/US20200368161A1

## CPC

- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/6911: {the form being a liposome}
- A61P 35/00: Antineoplastic agents
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

At present, there is a great need for the development of new tumor pH-shiftable nanoparticles that are effective to reduce side effects, enhance active tumor focusing, improve the cellular uptake, and nuclear/cytoplasmic targeting of chemotherapy and gene therapeutic. Hence, we designed novel solid lipid nanoparticles (SLN) and liposomes (Lip) to deliver microRNA and antineoplastic agent, respectively. The designed SLN and liposomes incorporating microRNA and anticancer drugs in the core, which is surrounded by lipids modified with peptide T (a ligand plus a cell-penetrating peptide) and a nucleus-targeted sequence of peptide R as the inner shell. Moreover, coating a pH-responsive polymer (PGA-PEG) on the outer layer of Lip-TR (PGA-Lip-TR) and SLN-T (PGA-SLN-T) can protect the peptide T and R from degradation by peptidases during systemic circulation and enhance directing to the acidic tumor sites. Collectively, these pH-shiftable nanoparticles may provide a novel and potential strategy for anticancer therapy.

## Claims

### Claim 1

A pH-shiftable nanoparticles, comprising:
a surface of a nanoparticle core, wherein the surface of the nanoparticle core is modified with a cationic target molecule,
a therapeutic agent inside the nanoparticle core; and
an outer layer, surrounding outside the surface of the nanoparticle core, the outer layer is coating with an acid-detachable polymer, wherein the acid-detachable polymers have the characteristic of responding to acidic pH;
wherein the cationic target molecule of the surface of the nanoparticle core and the acid-detachable polymer of the outer layer, which form a space and charge barrier via the electrostatic interaction.

### Claim 2 (depends on 1)

The pH-shiftable nanoparticles of claim 1, wherein the acid-detachable polymer is a PGA-PEG.

### Claim 3 (depends on 1)

The pH-shiftable nanoparticles of claim 1, wherein the nanoparticle core is L-α-phosphatidylcholine (PC), glycerol monostearate (monostearin), glycerol monopalmitate, glycerol monooleate, DSPE, DPPE, DOPE, DOTAP, DOTMA, SAINT 2, MC3 or KC2.

### Claim 4 (depends on 1)

The pH-shiftable nanoparticles of claim 1, wherein the therapeutic agent is a microRNA or a drug.

### Claim 5 (depends on 4)

The pH-shiftable nanoparticles of claim 4, wherein the microRNA is a hsa-miR-21 inhibitor or a microRNA mimic, wherein the microRNA mimic is selected from the group consisting of has-miR-122-5p, hsa-miR-125b-5p, has-miR-136-5p, has-miR-139-5p, hsa-miR-142-5p, has-miR-200c-3p and has-miR-320a.

### Claim 6 (depends on 4)

The pH-shiftable nanoparticles of claim 4, wherein the drug is selected from the group consisting of irinotecan, oxaliplatin, epirubicin, doxorubicin, afatinib and docetaxel.

### Claim 7 (depends on 1)

The pH-shiftable nanoparticles of claim 1, wherein the pH-sensitive polymer in the outer layer of pH-shiftable nanoparticles can respond to acidic pH to become protonated and detached from the inner surface layer of the nanoparticle core in pH 5-6.5 environment or tumor microenvironment.

### Claim 8 (depends on 3)

The pH-shiftable nanoparticles of claim 3, wherein the pH-shiftable nanoparticles is a solid lipid nanoparticles (SLN) or a liposomes (LIP).

### Claim 9 (depends on 1)

The pH-shiftable nanoparticles of claim 1, wherein the cationic target molecule is a peptide or a molecule.

### Claim 10 (depends on 9)

The pH-shiftable nanoparticles of claim 9, wherein the peptide is a cell-penetrating peptide.

### Claim 11 (depends on 10)

The pH-shiftable nanoparticles of claim 10, wherein the cell-penetrating peptide is TAT peptide (SEQ. NO 1).

### Claim 12 (depends on 9)

The pH-shiftable nanoparticles of claim 9, wherein the peptide is a tumor-homing peptide.

### Claim 13 (depends on 12)

The pH-shiftable nanoparticles of claim 12, wherein the tumor-homing peptide is N peptide (SEQ. NO 2).

### Claim 14 (depends on 9)

The pH-shiftable nanoparticles of claim 9, wherein the peptide is a bifunctional peptide, wherein the bifunctional peptide possesses features of tumor-homing moiety and cell-penetrating property.

### Claim 15 (depends on 14)

The pH-shiftable nanoparticles of claim 14, wherein the bifunctional peptide is T peptide (SEQ. NO 3).

### Claim 16 (depends on 15)

The pH-shiftable nanoparticles of claim 15, wherein the nanoparticle is constructed by the conjugate (DSPE-PEG-T) of lipid and the bifunctional peptide.

### Claim 17 (depends on 9)

The pH-shiftable nanoparticles of claim 9, wherein the peptide is a cell nucleus-targeted peptide.

### Claim 18 (depends on 17)

The pH-shiftable nanoparticles of claim 17, wherein the cell nucleus-targeted peptide is R peptide (SEQ. NO 4).

### Claim 19 (depends on 18)

The pH-shiftable nanoparticles of claim 18, wherein the nanoparticle is constructed by the conjugate (DSPE-PEG-R) of lipid and cell nucleus-targeted peptide.

### Claim 20 (depends on 1)

The pH-shiftable nanoparticles of claim 1, wherein the nanoparticle size is smaller than 150 nm with narrow size distribution.

### Claim 21 (depends on 1)

A pharmaceutical composition comprising:
an effective amount of pH-shiftable nanoparticles as claimed in claim 1.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, wherein pH-shiftable nanoparticles comprising:
a microRNA-loaded pH-shiftable nanoparticle, wherein the lipid is a mixture of a monoglyceride, a cationic lipid and a surfactant, and the therapeutic agent is a microRNA; and
a drug-loaded pH-shiftable nanoparticle, wherein the lipid is a lipid bilayer composed of a phospholipid and the therapeutic agent is an anticancer drug.

### Claim 23 (depends on 20)

The pharmaceutical composition of claim 20, wherein the microRNA is a hsa-miR-21 inhibitor or a microRNA mimic, wherein the microRNA mimic is selected from the group consisting of has-miR-122-5p, hsa-miR-125b-5p, has-miR-136-5p, has-miR-139-5p, hsa-miR-142-5p, has-miR-200c-3p and has-miR-320.

### Claim 24 (depends on 21)

The pharmaceutical composition of claim 21, wherein the microRNA-loaded pH-shiftable nanoparticle is PGA-SLN-T and the microRNA is miR-320.

### Claim 25 (depends on 20)

The pharmaceutical composition of claim 20, wherein the anticancer drug is selected from the group consisting irinotecan, oxaliplatin, epirubicin, doxorubicin, afatinib and docetaxel.

### Claim 26 (depends on 23)

The pharmaceutical composition of claim 23, wherein the drug-loaded pH-shiftable nanoparticle is PGA-Lip-TR and the anticancer drug is Oxa.

### Claim 27 (depends on 20)

The pharmaceutical composition of claim 20, wherein the pH-shiftable nanoparticles is modified with peptide T and peptide R.

### Claim 28 (depends on 20)

A method for treating cancer in a subject, comprising: administering an effective amount of pH-shiftable nanoparticles as claim 20, comprising:
a microRNA-loaded pH-shiftable nanoparticle, wherein the lipid is a mixture of a monoglyceride, a cationic lipid, and a surfactant and the therapeutic agent is a microRNA; and
a drug-loaded pH-shiftable nanoparticle, wherein the lipid is a lipid bilayer composed of a phospholipid and the therapeutic agent is an anticancer drug.

### Claim 29 (depends on 28)

The method of claim 28, wherein the cancer comprises colorectal cancer, head and neck cancer, gastric cancer or cervical cancer.

### Claim 30 (depends on 28)

The method of claim 28, wherein the anticancer drug is selected from the group consisting of irinotecan, oxaliplatin, epirubicin, doxorubicin, afatinib and docetaxel.

### Claim 31 (depends on 28)

The method of claim 28, wherein the microRNA is a hsa-miR-21 inhibitor or a microRNA mimic, wherein the microRNA mimic is selected from the group consisting of has-miR-122-5p, hsa-miR-125b-5p, has-miR-136-5p, has-miR-139-5p, hsa-miR-142-5p, has-miR-200c-3p and has-miR-320.

### Claim 32 (depends on 28)

The method of claim 28, wherein the pH-shiftable nanoparticles is coated with a pH-sensitive polymer (PGA-PEG) on the outer layer, which can prolong the systemic circulation time of nanoparticles in blood and enhance passive targeting to the tumor sites via the enhance permeability and retention (EPR) effect.

### Claim 33 (depends on 28)

The method of claim 28, wherein the pH-shiftable nanoparticles has de-coating of pH-sensitive polymers on the outer layer at pH 6.0 to expose peptide T and peptide R for increasing the uptake of nanoparticles into cancer cells.
